iBio
iBio, Inc. is a biotechnology company based in New York that specializes in contract development and manufacturing services, focusing on plant-based protein expression technologies for vaccines and therapeutic proteins. The company’s lead candidate, IBIO-100, is under development for the treatment of systemic scleroderma and related conditions. Additionally, iBio is advancing vaccine candidates IBIO-200 and IBIO-201 for the prevention of COVID-19 and IBIO-400 for classical swine fever. iBio offers comprehensive services, including process development, manufacturing, filling, and bioanalytical services, to both collaborators and third-party clients. The company has established various collaborations and license agreements to enhance its capabilities, including partnerships for biosimilar development and vaccine research. Its innovative iBioLaunch platform enables rapid and cost-effective production of biologics, significantly improving response times for emerging health threats and reducing operational costs compared to traditional methods. Through its dual focus on biopharmaceuticals and bioprocessing, iBio aims to contribute to the treatment of a wide range of diseases, including fibrotic diseases, cancers, and infectious diseases.
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs. RubrYc Therapeutics using disruptive innovation to deliver fresh insights into the design and development of therapeutic antibodies. Inspired by recent advancements in molecular library synthesis, massively parallel screening and computing, they are forging a new path for information-driven discovery of therapeutic antibodies.
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs. RubrYc Therapeutics using disruptive innovation to deliver fresh insights into the design and development of therapeutic antibodies. Inspired by recent advancements in molecular library synthesis, massively parallel screening and computing, they are forging a new path for information-driven discovery of therapeutic antibodies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.